Vasculitis & polymyalgia rheumatica
Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases
Authors' conclusion
Tofacitinib, which can induce remission, prevent recurrence and taper the GC dosage, was well tolerated and may be an effective agent for the treatment of EGPA.
Study context
- Population
- Active eosinophilic granulomatosis with polyangiitis (EGPA) patients from a prospective single-centre cohort; 5 newly diagnosed, 6 refractory to glucocorticoids (GCs) plus immunosuppressants
- Participants
- 11 patients
- Outcome
- Efficacy and safety of tofacitinib (treatment response)
Methodological detailssingle-centre, pilot study, single-arm
- Single-centre
- Pilot study
- Single-arm
Main finding
As reported in the abstract
Response rate (CR + PR)
Response at 3 months
10 of 11
Response rate (complete remission (CR) + partial remission (PR)) at 6 and 9 months
100%
CR rate at 6 months
60%
CR rate at 9 months
80%
Observational data: associations, not effects.
Further findings
Inflammatory parameters, eosinophils and GC dose · 6 months
- ESR and CRP normalized, eosinophils count significantly decreased and GC dose tapered in all patients
Relapse · median follow-up 15 months
- No relapse
Original publication
Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases. Rheumatology (Oxford). Published 18 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →